NASDAQ · RIGL
Rigel Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for RIGL: Nov 05, 2026
Rigel Pharmaceuticals, Inc. Common Stock is expected to report earnings on 11/05/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $0.87. The reported EPS for the same quarter last year was $1.46.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.87 | $0.99 | $0.75 | 2 |
| Dec 2026 | $0.93 | $0.94 | $0.91 | 2 |
| Mar 2027 | $0.49 | $0.49 | $0.49 | 1 |
| Jun 2027 | $0.80 | $0.80 | $0.80 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · The Motley Fool · MarketBeat · RTTNews- Zacks · Oct 13, 10:27 AM EDTReasons Why Investors Should Consider Betting on Arvinas StockARVN's first FDA-approved PROTAC degrader validates its technology, while a diverse pipeline targeting cancer and neurological disorders offers further growth potential.
- The Motley Fool · Aug 11, 8:46 PM EDTRigel (RIGL) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 4, 10:03 PM EDTRigel Pharmaceuticals Q2 Earnings Call HighlightsRigel Pharmaceuticals (NASDAQ:RIGL) reported second-quarter 2026 total revenue of $78.7 million and net income of $17.3 million, while outlining plans to launch newly licensed breast cancer therapy VEPPANU in mid-August. The company generated $67 million in U.S. net product sale
- Zacks · Aug 4, 5:15 PM EDTRigel Pharmaceuticals (RIGL) Q2 Earnings Miss EstimatesRigel (RIGL) delivered earnings and revenue surprises of -3.30% and +14.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 7, 8:20 AM EDTBioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock?Bioventus (BVS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- RTTNews · Jul 1, 11:26 AM EDTRigel Appoints Alison Hannah As CMO To Succeed Lisa Rojkjaer(RTTNews) – Rigel Pharmaceuticals, Inc. (RIGL), a commercial-stage biotechnology company, announced on Wednesday the appointment of Alison Hannah as Executive Vice President and Chief Medical Officer, succeeding Lisa Rojkjaer.
- RTTNews · Jul 1, 9:20 AM EDTRigel CMO Lisa Rojkjaer Retires, Alison Hannah Appointed As New CMO(RTTNews) – Rigel Pharmaceuticals Inc. (RIGL) announced that Lisa Rojkjaer retired as Chief Medical Officer of the company on July 1, 2026, and Alison Hannah was appointed as the new CMO the same day.
- RTTNews · May 15, 8:08 AM EDTWeekly Buzz: Lilly Posts Positive Trial Data, Rigel Licenses PROTAC Drug, BMY Strikes $15.2B Deal(RTTNews) – This week's biotech highlights Lilly's strong Phase 3b maintenance results for Zepbound and Foundaya, Rigel's global license for the first FDA-approved PROTAC therapy Veppanu, and Bristol Myers Squibb's $15.2 billion collaboration with Hengrui Pharma. The regulatory f
- RTTNews · May 12, 7:50 AM EDTRigel Pharma Signs Licensing Agreement With Arvinas And Pfizer For Veppanu(RTTNews) – Rigel Pharmaceuticals, Inc. (RIGL) on Tuesday said it has entered into a global license agreement with Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) to develop, manufacture and commercialize beast cancer treatment Veppanu.
- RTTNews · May 5, 9:37 PM EDTRigel Pharmaceuticals Inc. Profit Falls In Q1(RTTNews) – Rigel Pharmaceuticals Inc. (RIGL) announced earnings for first quarter that Dropped, from last year
- Zacks · May 5, 6:05 PM EDTRigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue EstimatesRigel (RIGL) delivered earnings and revenue surprises of -40.54% and -2.39%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Apr 29, 10:00 AM EDTGuardian Pharmacy Services (GRDN) Reports Next Week: Wall Street Expects Earnings GrowthGuardian Pharmacy (GRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Rigel Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.